

ABSTRACT OF THE DISCLOSURE

[00083] The invention relates to uses of kappa-conotoxin PVIIA (κ -PVIIA), analogs and derivatives for activating ATP-sensitive K^+ channels. The activation of ATP-sensitive K^+ channels is useful for opening K_{ATP} channels which can be used to treat a wide range of disease and injury states, including cerebral and cardiac ischemia and asthma.